SL Science Holding Ltd SLBT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.55
- Day Range
- $1.53–1.55
- 52-Week Range
- $1.42–14.48
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 560.76M
- Market Cap
- $857.96M
- Volume/Avg
- 24,823 / 79,548
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 390.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 20
- Website
- https://www.slbtgroup.com
Valuation
|
Metric
|
SLBT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 390.51 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLBT
|
|---|---|
Quick Ratio | 2.96 |
Current Ratio | 3.05 |
Interest Coverage | — |
Quick Ratio
SLBT
Profitability
|
Metric
|
SLBT
|
|---|---|
Return on Assets (Normalized) | −78.81% |
Return on Equity (Normalized) | −89.94% |
Return on Invested Capital (Normalized) | −87.33% |
Return on Assets
SLBT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|V%Z#^d | LOCK|<&Q# | $127B | |||
| Moderna Inc
MRNA
| LOCK|kPz@!S | LOCK|tn | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@Tbqw^ | LOCK|<X$@> | $81B | |||
| argenx SE ADR
ARGX
| LOCK|KV!hV! | LOCK|>z% | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|yyT@R@Q | LOCK|!&X | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|YYlLdM# | LOCK|j!NW | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|db?&QDL$ | LOCK|WDHD@ | $27B | |||
| Incyte Corp
INCY
| LOCK|$?%Rc>x | LOCK|pRS | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|C%#p>C^ | LOCK|f$Q | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?g#N^#^ | LOCK|$zr | $14B |
United States